BioSpace News Archive

Surgalign Holdings, Inc. (Nasdaq: SRGA), a global medical technology company focused on advancing spine surgery and improving patient outcomes, including through the application of digital technology, today announced that the management team will present at the Sidoti Virtual Investor Conference on Thursday, March 25, 2021.

BIOASIS TECHNOLOGIES INC. announced that it has applied for approval from the TSX Venture Exchange to extend the expiry date of 5,797,795 common share purchase warrants issued to subscribers pursuant to the private placement of units which closed on April 11, 2017 and to amend the exercise price of the warrants.

Anixa Biosciences, Inc. (NASDAQ: ANIX) (“Anixa” or the “Company”), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis

Thermo Fisher Scientific, the world leader in serving science, has further expanded its Thermo Scientific General Purpose Pro Centrifuge Series with the addition of two new models designed to meet the needs of biopharmaceutical, cell and gene therapy, and academic research laboratories, as well as clinical diagnostic facilities

EpimAb Biotherapeutics, a clinical stage biotech company specializing in bispecific antibody development, announced today the closing of a $120 million Series C financing round.

Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.

BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced the signing of a definitive merger agreement to acquire Global Cooling, Inc., operating as Stirling Ultracold

Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist” or “the Company”) announced today that the Division of Nonmalignant Hematology at the U.S. Food and Drug Administration (“FDA”) has provided important feedback during an End-of-Phase 2 meeting on rusfertide (PTG-300), an investigational new treatment for polycythemia vera (“PV”)

BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced financial results for the fourth quarter and year ended December 31, 2020.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the 10th Annual J.P. Morgan Napa Valley Forum.